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Sporadic inclusion body myositis (SIBM) is character-
ized by vacuolar degeneration of muscle fibers and in-
trafiber clusters of paired helical filaments with abnor-
mal amyloid deposition. Because of their potential
involvement in other degenerative disorders, we have
examined the expression of transglutaminases (TGases)
in normal and SIBM tissues. We report that at least two
different enzymes, the ubiquitous TGase 2 as well as the
TGase 1 enzyme, are present in muscle tissues. However,
in comparison with normal tissue, the expression of
TGases 1 and 2 was increased 2.5- and 4-fold in SIBM,
accompanied by about a 20-fold higher total TGase ac-
tivity. By immunohistochemical staining, in normal
muscle, TGase 2 expression was restricted to some en-
domysial connective tissue elements, whereas TGase 1
and b-amyloid proteins were not detectable. In SIBM
muscle, both TGases 1 and 2 as well as amyloid proteins
were brightly expressed and co-localized in the vacuo-
lated muscle fibers, but none of these proteins colocal-
ized with inflammatory cell markers. Next, we isolated
high molecular weight insoluble proteins from SIBM
muscle tissue and showed that they were cross-linked by
about 6 residues/1000 residues of the isopeptide bond.
Furthermore, by amino acid sequencing of solubilized
tryptic peptides, they contain amyloid and skeletal mus-
cle proteins. Together, these findings suggest that ele-
vated expression of TGases 1 and 2 participate in the
formation of insoluble amyloid deposits in SIBM tissue
and in this way may contribute to progressive and de-
bilitating muscle disease.
Sporadic inclusion body myositis (SIBM)1 is the most com-
mon myopathy in individuals over the age of 50 years. SIBM,
first described in 1971 (1), is characterized by weakness in
quadriceps, triceps, and foot extensor muscle systems leading
to severe muscle disability (1, 2). Although extensive studies
have been reported concerning the clinical, pathological, and
immunological features of the disease, its etiology and patho-
genesis are not yet clear. Histology of SIBM muscle biopsy
tissues reveals abnormal muscle fibers showing rimmed vacu-
oles, endomysial inflammation, intracellular amyloid deposi-
tion, and abundant 15–18-nm tubulofilaments within the vac-
uolated muscle fibers (3). Recent studies have suggested that
overexpression of the b-amyloid precursor protein (b-APP) and
its abnormal deposition may induce a muscle fiber destruction
(4, 5). Interestingly, in this regard there are molecular-patho-
logic similarities between SIBM and Alzheimer’s disease (3, 6).
One of the pathologic hallmarks of Alzheimer’s disease is the
presence of neuritic plaques consisting of b-amyloid peptide
(b-A) polymers, perhaps arising from cross-linking by transglu-
taminase (TGase) activity (7–10).
TGases (EC 2.3.2.13) are calcium-dependent cross-linking
enzymes that form an isopeptide Ne-(g-glutamyl)lysine bond
between peptide-bound glutamine and lysine residues. In this
way they stabilize intra- and extracellular proteins into mac-
romolecular assemblies that are used for a variety of essential
physiological purposes such as barrier function in epithelia,
apoptosis, extracellular matrix formation, etc. (11–15). To date,
a number of reports have described the presence of the ubiqui-
tous TGase 2 enzyme in normal muscle tissues (16–19), but the
role of other TGases has not been explored. In addition, there is
evidence that under certain circumstances, inappropriate
cross-linking by TGases might lead to pathological conditions
(10, 13–15). With this in mind and the possible involvement of
TGases in the pathology of neurodegenerative diseases, in this
study we have investigated TGase expression in normal and
SIBM muscle tissues.
MATERIALS AND METHODS
Human Samples—Biopsies from vastus lateralis muscle tissue were
obtained from three patients with diagnostic criteria typical of SIBM
(20). Also, tissue from the same muscle site from three normal aged-
matched individuals without known muscle disease was obtained as
byproducts of unrelated surgical procedures. All tissues were obtained
with informed consent at the Severance Hospital (Seoul, Korea). Four
frozen tissues (20 mm thickness) were homogenized using a Teflon
pestle with 0.1 M Tris acetate (pH 7.5), 1 mM EDTA, containing protease
inhibitors (5 mg/ml leupeptin, 5 mg/ml aprotinin, 50 mg/ml calpain
inhibitor I, 100 mg/ml bestatin, and 1 mM phenylmethylsulfonyl fluo-
ride). The homogenates were used for TGase activity assays and West-
ern blotting analysis with b-A antibody. To prepare total RNA for
RT-PCR, control and SIBM muscle tissues were homogenized directly
in a glass tube using a Teflon pestle by adding Trizol reagent (100
mg/ml) (Life Technologies, Inc.) using the manufacturer’s instructions.
Conditions for TGase Assay—A modified TGase assay method was
used to determine the enzymatic activity by measurement of the incor-
poration of [1,4-14C]putrescine into succinylated casein (21). The sam-
ples were mixed in a reaction mixture (0.5 ml) containing 0.1 M Tris
acetate, pH 7.5, 1% succinylated casein, 1 mM EDTA, 10 mM CaCl2,
0.5% lubrol PX, 5 mM dithiothreitol, 0.15 M NaCl, and 0.5 mCi of
[14C]putrescine (NEN Life Science Products; 118 Ci/mol). Following
incubation at 37 °C for 1 h, the reaction was terminated by the addition
of 4.5 ml of cold (4 °C) 7.5% trichloroacetic acid. The trichloroacetic
acid-insoluble precipitates were collected onto GF/A glass fiber filters,
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washed with cold 5% trichloroacetic acid, dried, and counted.
RT-PCR Analyses—Samples of total RNA (0.01, 0.1, or 1 mg) were
reverse transcribed at 42 °C using the first strand synthesis kit (Roche
Molecular Biochemicals), and then PCR was performed for the tran-
scripts of TGase 1, TGase 2, b-APPs, and b-actin using specific primer
sets. All PCRs contained the following in 20 ml: 1.5 mM MgCl2, 200 mM
dATP, 200 mM dGTP, 200 mM dTTP, 100 mM dCTP, 10 mCi of 32P-dCTP
(3000 Ci/mmol), a 0.2 mM concentration of each upstream and down-
stream primer, 0.5 units of Taq polymerase, and variable amounts of
templates as required.
The specific RT-PCR primers were designed in regions of no sequence
homology between each human TGase, and were confirmed with human
foreskin mRNA. The PCR primer sequences are as follows: TGase 1
sense strand, 59-GAT TGT CTT CAA GAA CCC CCT TCC C-39; TGase
1 antisense strand, 59-TCA TCT GAC TCC AGT CCC ATT GCT C-39;
TGase 2 sense strand, 59-CTC GTG GAG CCA GTT ATC AAC AGC
TAC-39; TGase 2 antisense strand, 59-TCT CGA AGT TCA CCA CCA
GCT TGT G-39; b-actin sense strand, 59-ATC TGG CAC ACC TTC TAC
AAT GAG CTG CG-39; and b-actin antisense strand, 59-CGT CAT ACT
CCT GCT TGC TGA TCC ACA TCT GC-39. Oligonucleotide primers
originally designed by Golde et al. (22) were used that simultaneously
amplified cDNA sequence encoding b-APP695, b-APP714, b-APP751,
and b-APP770. The sequence of the forward primer was 59-CAC CAC
AGA GTC TGT GGA AG-39; the sequence of reverse primer was 59-AGG
TGT CTC GAG ATA CTT GT-39.
The PCRs were done with conditions of one cycle of 95 °C (2 min),
different numbers of cycles at 55 °C (30 s) or 65 °C (30 s), and one final
cycle at 72 °C (7 min) with a Perkin-Elmer 9600 PCR machine. In order
to ensure a linear relationship between the amount of PCR product and
amount of total RNA, we used 25 cycles for b-actin and TGase 2 at
55 °C, 35 cycles for b-APP at 55 °C, and 35 cycles for TGase 1 at 65 °C.
The higher stringency for TGase 1 was required to obtain a specific
band of the correct size but suffered a much lower yield of product. The
products of the PCRs were separated by gel electrophoresis on 6% TBE
gels, dried, and quantitated by use of a PhosphorImager (Molecular
Dynamics, Inc., Sunnyvale, CA). To confirm the cDNA sequences, the
products of RT-PCRs were excised from gels and ligated into the T-
vector (Novagen). After selection of colonies, DNA sequencing was per-
formed by the Sanger method. The sequences exactly matched to the
human TGase 1 or 2 cDNA sequences (23, 24).
Since no products were obtained from the other transcripts at 65 °C,
direct comparisons of amounts of each transcript were not possible.
Therefore, we used an established method to generate semiquantitative
comparative data on the relative amounts of the various transcripts
(25). This measures the relative differences in the initial numbers of
transcripts between two samples by use of titration analyses of a
dilution series of RNA, followed by amplification and measurement of
the products. In these cases, the ratio of unlabeled to labeled dCTP used
in the amplification reactions was in a large excess. As a second internal
control, we constructed a standard curve using plasmid cDNAs of
TGases 1 and 2 as templates and demonstrated a linear reaction rate
between the amount of [32P]dCTP incorporated and a .3-order of mag-
nitude concentration range for the amount of each transcript. Since
these standard curves had the same slopes for each transcript over a
1000-fold range of the total RNA template (Fig. 2), direct comparisons
of relative amounts of each specific transcript in the tissues are
possible.
Immunohistochemistry—7-mm transverse frozen serial sections of
muscle biopsies were obtained from three SIBM patients and three
age-matched normal individuals, and these were used for single and
double immunofluorescence techniques. Gomori trichrome staining was
also performed on adjacent sections (Figs. 3 and 4).
Single Immunohistochemistry—Sections were fixed in acetone at
4 °C for 10 min, rinsed in 50 mM Tris-buffered saline (pH 7.5) for 15
min, and incubated for 30 min with blocking solution containing 2%
bovine serum albumin and 5% normal goat serum (for TGase 2, b-APP,
and b-amyloid) or 5% horse serum (for TGase 1). The sections were then
incubated overnight at 4 °C using the following antibodies: polyclonal
anti-human TGase 1 made in goat (26) diluted 1:200; polyclonal anti-
human TGase 2 made in rabbit (10) diluted 1:200; and monoclonal
anti-b-amyloid precursor protein and b-amyloid peptide (Zymed Labo-
ratories Inc., San Francisco, CA) diluted 1:10 (27). After washing for 30
min in Tris-buffered saline, the sections were incubated with biotiny-
lated goat anti-mouse IgG (for b-APP and b-amyloid), biotinylated goat
anti-rabbit IgG (for TGase 2), or biotinylated horse anti-goat IgG (for
TGase 1), followed by fluorescein isothiocyanate-avidin D (Vector Lab-
oratory, Burlingame, CA). Slides were mounted in Vectashield (Vector)
and examined with a microscope equipped with epifluorescence optics.
Controls for staining specificity were preabsorption of the primary
TGase antibodies with corresponding specific protein antigens, omis-
sion of the primary antibody, or its replacement with nonimmune
serum. To block nonspecific binding of antibody to Fc receptors, sections
were preincubated with 1:10 diluted normal goat serum.
Double Immunohistochemistry Using Confocal Microscopy—This
was done to examine colocalization of TGase 1 and TGase 2 antigens
with b-APP, b-amyloid, and cytotoxic CD81 cells. Frozen sections were
prepared as above and incubated overnight with the polyclonal anti-
bodies against TGase 1 or TGase 2 followed by biotinylated secondary
antibodies and fluorescein-conjugated avidin. The sections were then
incubated with one of the following monoclonal antibodies: b-APP (di-
luted 1:10), b-amyloid peptide (diluted 1:10), or CD8 (dilution 1:40,
Coulter Immunotech, Miami, FL). Finally, the sections were treated
with trimethylrhodamine isothiocyanate-conjugated secondary anti-
body against mouse IgG. Similar controls to the above were used. To
avoid cross-reactivity despite blocking, we confirmed the results in
serial sections stained separately with each of the primary antibodies.
Confocal microscopy was used for more accurate co-localization of the
antigens on the surfaces of cells or muscle fibers. Images were collected
as a single image, not multiply integrated, on a microscope (model LSM
410 with a 40 3 1.2 NA Apochromat objective; Carl Zeiss, Thornwood,
NY). The 488- and 568-nm lines of a krypton/argon laser were used for
fluorescence excitation.
Western Blotting—Total SIBM muscle lysate (20 mg/well) was ap-
plied on 4–20% gradient SDS gels using Tricine buffers and then
transferred to polyvinylidene difluoride membranes. Western blotting
was performed as established previously (26). The concentration of
polyclonal anti-b-amyloid peptide (Zymed Laboratories Inc., San Fran-
cisco, CA) was 5 mg/ml for primary antibody and 0.1 mg/ml for secondary
antibody. The blot was then developed by enhanced chemiluminescence
(Pierce). Subsequently, the identified very high molecular weight and
;70-kDa bands were cut out, eluted into SDS buffer containing Tricine,
freed of SDS by ion pair extraction (28), and subjected to amino acid
analysis.
Purification of Insoluble High Molecular Weight Proteins and Meas-
urement of Isopeptide Cross-link—Four frozen tissue sections (20-mm
thickness) were boiled for 10 min in an extraction solution consisting of
2% (w/v) SDS and 0.1% (w/v) dithiothreitol. Insoluble proteins were
sedimented by centrifugation for 5 min at 13,500 3 g. They were then
resuspended and extracted three more times (29, 30) and finally sus-
pended in 0.1 M N-ethylmorpholine acetate (pH 8.3). An aliquot (10%)
was used for quantitation of total protein amount by amino acid anal-
ysis. Another 30% was subjected to total enzymic digestion to release
the free Ne-(g-glutamyl)lysine isopeptide cross-link, which was then
resolved and quantitated by amino acid analysis (30). The isopeptide
elutes immediately after methionine. In a related set of experiments,
the isopeptide content of tissue sections was determined without prior
extraction.
Peptide Sequencing—The remaining 50% of the insoluble proteins
(;10 mg) were digested with trypsin (Sigma; sequencing grade, about
3% by weight, 6 h at 37 °C), and peptides were resolved on a 23 150-mm
C18 HPLC column (Phenomenex, nucleosil 3) using a 20–75% acetoni-
trile gradient and using 220- and 280-nm optics. Twenty-six peaks, all
of which contained aromatic residues and thus appeared well delin-
eated due to their higher absorption at 220 nm, were collected, dried,
bound to a solid support, and analyzed in a Beckman LF3500 gas-liquid
phase sequencer for 10 Edman degradation cycles. The phenylthiohy-
dantoin-derivatized amino acid(s) released at each cycle were resolved
and quantitated by HPLC (31).
RESULTS
Expression of TGases 1 and 2 Is Increased in SIBM Tis-
sue—We ascertained three SIBM patients who had developed
weakness of the quadriceps muscles, atrophy and weakness of
the finger flexors, and weakness of foot extensors, all features
classically seen in SIBM (20). Histological and immunopatho-
logical features of muscle biopsies showed a myopathy with
variation of fiber size, rimmed vacuoles, and endomysial in-
flammation infiltrates surrounding and invading nonnecrotic
muscle fibers (data not shown, but see Fig. 3). Total TGase
activity was measured in tissue extracts and found to be 16-fold
higher in biopsy samples from the SIBM patients compared
with normal tissues (Fig. 1).
Elevated Levels of TGase 1 and TGase 2 mRNAs in SIBM
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Tissues—To characterize the basis of this increase, we em-
ployed semiquantitative RT-PCR to estimate the relative levels
of mRNAs for TGases 1 and 2 and b-APPs in normal and SIBM
tissues. Because it was necessary to use different conditions for
PCR for the transcripts of interest, direct estimates of their
amounts in the tissues were not possible. Therefore, we ini-
tially determined conditions necessary to establish the linear
range for the PCRs for the TGase 1 and TGase 2 transcripts
using plasmid DNAs as templates by measurement of
[32P]dCTP incorporated during the PCR (Fig. 2A). Then we
performed titration analyses with three different amounts of
muscle template RNAs. We found that there was likewise a
linear relationship between total RNA amounts (Ao) and PCR
(P) product for four mRNAs of interest, and b-actin as an
internal control (Fig. 2B). Because the amount of target mRNA
is a constant proportion of the total for each dilution, the
relative difference in the numbers of specific mRNA molecules
is proportional to the relative differences in slopes (25), from
which we could obtain semiquantitative comparative data (Fig.
2C). The data reveal several issues. First, we detected signifi-
cant amounts of TGase 1 mRNA, so that this is the first report
on the presence of TGase 1 in muscle tissues. Second, the
amount of the b-actin control was very consistent for the three
normal and three SIBM samples. Third, the values for the four
transcripts of interest in each of the three normal or SIBM
samples varied by ,20%. Notably, however, there was a 2.5-
fold increase of the TGase 1 and 4-fold increase of the TGase 2
mRNA levels, respectively, in the SIBM tissues over the nor-
mal tissues. TGase 3 expression was examined but not detected
in normal and SIBM tissues (data not shown). Furthermore,
there was a 4-fold increase of b-APP-770 mRNA and a 7.5-fold
increase of b-APP-751 mRNA in SIBM tissues. These two re-
sults are consistent with a previous observation in SIBM pa-
tients (9).
Co-localization of Antigens for TGases 1 and 2 and b-Amy-
loid in SIBM Tissue—In order to confirm these mRNA data, we
examined the localization of TGase and amyloid antigens using
immunohistochemical staining of muscle tissues from normal
and SIBM individuals and using antibodies highly specific for
TGase 1 (26) and TGase 2 (10) as well as for b-A (32) and b-APP
(33). In normal control individuals, only TGase 2 positively
stained some endomysial connective tissues (Fig. 3c), whereas
staining for TGase 1 (Fig. 3b), b-APP (Fig. 3d), and b-A (not
shown) antigens was very weak or negative. In order to obtain
higher resolution, we used confocal microscopy. In representa-
tive sections of diseased muscle tissues from biopsies of the
three patients, trichrome staining showed vacuoles and inflam-
mation with lymphocytic infiltration (Fig. 3, e, i, m, and q),
features that are typical for SIBM. The immunofluorescence
staining of TGase 1 occurred in endomysial connective tissue
and was very apparent near and in the vacuoles of SIBM (Fig.
3, f and n). The staining of TGase 2 was notably increased in
the endomysium connective tissue, sarcolemma at the endom-
ysium, and the vacuoles (Fig. 3, j and r). Thus, both TGase
enzymes were strongly localized in the vicinity of the vacuolar
inclusions. In addition, b-APP (Fig. 3, g and k) and b-A (Fig. 3,
o and s) were strongly expressed in and near the vacuoles. To
examine these expression patterns in more detail, we also used
double immunofluorescence staining with confocal microscopy.
We consistently observed close overlap in the expression of
TGase 1 and b-APP (Fig. 3h) or b-A (Fig. 3p) as well as for
TGase 2 and b-APP (Fig. 3l) or b-A (Fig. 3t). Consistent with
the above RT-PCR data, immunohistostaining of TGase 3 using
a specific anti-human TGase 3 antibody showed no positive
staining either in the normal or SIBM tissues (data not shown).
Inflammatory Cell Infiltrates in SIBM Tissues Do Not Co-
localize with TGases—Next, we wanted to determine whether
the inflammatory cells evident in the SIBM tissues contained
TGases. We performed double immunofluorescence on serial
sections using a CD8 T cell specific antibody (Fig. 4), since such
cells account for 80%, whereas CD4-positive macrophages ac-
count for only about 20% of the invasive inflammatory cells of
SIBM (33). This antibody did not stain significantly normal
muscle tissue (not shown). Notably, however, the CD8-positive
T cells were evident in the infiltrate of SIBM tissues, as ex-
pected (27), but did not significantly co-localize with the TGase
2 (Fig. 4c) or TGase 1 and b-APP antigens (data not shown).
These data suggest that the invasive inflammatory cells are not
a major source of the overall increased TGase presence in SIBM
tissues.
Recovery of High Molecular Weight Proteins from SIBM Tis-
sue That Contain Isopeptide Cross-links—Next, we investi-
gated whether the increased expression of TGases and the
large increase in TGase activity seen in SIBM contributed to
the formation of cross-linked protein deposits. We performed
Western blotting of total lysates of muscle biopsies using a
highly specific polyclonal anti-b-A peptide antibody (Fig. 5).
Only minor immunoreactive products were seen in any of the
normal muscle tissue samples. However, in all three SIBM
tissue samples, positive bands of about 110 kDa were identi-
fied, which are likely to be the b-APP-770/751 species as pre-
viously reported (34). Interestingly, this 110-kDa band was not
notably increased in the SIBM tissues as compared with nor-
mal tissues, but instead very high molecular mass proteins
(.400 kDa) that remained at the interface of the separation gel
were prominent instead. We also observed an increase of two
60–70-kDa protein bands in the SIBM samples (Fig. 5), which,
following excision from the blot and amino acid analysis after
acid hydrolysis, contained only trace amounts of protein (,5%
of the high molecular weight band and insufficient for micro-
sequencing analysis). Thus, the 60–70-kDa bands reactive with
the specific antibody may be processed forms of b-APP.
To confirm that these high molecular weight b-APP-reactive
proteins arise from TGase cross-linking, we employed the
method established for isolation of the insoluble cornified cell
envelope of the epidermis (29, 30). Muscle biopsies were ex-
haustively extracted by boiling with a solution containing 2.0%
SDS and 0.1% dithiothreitol, and insoluble proteins were col-
lected by centrifugation. By amino acid analyses, the insoluble
proteins constituted 15% of the total protein of the SIBM tissue
sections. In contrast, we could recover only trace amounts of
insoluble proteins from normal tissue samples (,0.1% of total
protein). An aliquot of insoluble proteins from the SIBM tissues
was then subjected to total enzymic digestion in order to re-
lease the free isopeptide cross-link. Following quantitation by
FIG. 1. The expression of TGases 1 and 2 is increased in SIBM
muscle tissues. The TGase activities of total homogenate from SIBM
tissues was about 20-fold increased over the matched normal control.
These data are the averages 6 S.D. from three normal individuals as
well as tissues from the three SIBM patients.
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amino acid analysis (30), we found 0.6 residues of cross-link/
100 residues. Interestingly, this is similar to the 1 residue/100
residues seen in the skin (30). As controls for these experi-
ments, we determined the total amounts of cross-link in the
intact tissue sections, which were 1–2 and 8–10 residues of
cross-link/10,000 residues in normal and SIBM tissues, respec-
tively. The former value, which is similar to that found in other
normal tissues such as liver and brain, may represent a back-
ground degree of apoptosis (10, 14, 15). The latter value is
consistent with the content of insoluble proteins recovered from
the SIBM tissues and thus indicates that the higher levels of
cross-link in SIBM tissue originate from the insoluble proteins.
Accordingly, these data afford the first direct report of the
identification of the isopeptide cross-link in muscle tissues in
vivo. Most significantly, the cross-link level is elevated 60-fold
in the insoluble inclusion bodies of SIBM tissues.
b-APP Proteins and Muscle Proteins Are Present in the In-
soluble Protein Fractions of SIBM Tissue—The data of Fig. 5
are consistent with the possibility that cross-linked homo- or
heteropolymers of b-APP proteins were generated by the in-
FIG. 2. Semiquantitative compara-
tive RT-PCR shows increased expres-
sion of TGase 1 and 2 and b-APP pro-
teins. RT-PCR products were quantitated
by PhosphorImager analyses following
[32P]dCTP labeling. First, the linear range
for the optimization of the reactions was
ascertained for TGases 1 and 2 using avail-
able plasmid cDNAs (A). Then the relative
levels in normal and SIBM muscle tissues
of five mRNA species were determined
with different amounts of total RNA (B).
From the slopes for the five mRNAs, the
comparative relative amount of each
mRNA species was determined (C). These
data are the averages 6 S.D. from three
normal individuals as well as tissues from
the same three SIBM samples. Variations
between the three normal and SIBM sam-
ples were ,20%.
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creased TGase activity. To rigorously identify the protein con-
tent of the cross-linked high molecular weight products, a
10-mg aliquot was subjected to digestion with trypsin, and the
peptides were resolved by HPLC using a microbore column
(Fig. 6). The 220-nm trace revealed numerous peaks. However,
since each of these contained aromatic amino acids (280-nm
trace not shown), it should be noted that the apparent sizes and
shapes of the peaks are not necessarily representative of the
amounts of peptide material contained within them. In addi-
tion, the HPLC trace shows a high background of many other
poorly resolved peptide peaks. A total of 26 aromatic peaks was
recovered for microsequencing, and the amounts ranged from 2
to 10 pmol. Ten peptides afforded unambiguous identification
from data base searches (Table I). Notably, five peptides con-
tained sequences from either the extra- or intracellular domain
of the b-APP protein. We also recovered several identifiable
FIG. 3. Immunohistochemical analyses reveal colocalization of TGases and b-amyloid proteins in SIBM muscle tissue. The frozen
sections were from normal control (a, b, c, and d) and SIBM (e–t). Gomori trichrome staining was performed in a, e, i, m, q. The antibodies used
were anti-TGase 1 (b, f, h, n, p), anti-TGase 2 (c, j, l, r, t), anti-b-APP (d, g, h, k, l), anti-b-A (o, p, s, t), and double immunostaining with b-APP
(h, l) or with b-A (p, t). TGase 1, b-APP, and b-A antigens were almost undetectable in normal tissue, although we detected trace amounts of mRNA
by RT-PCR (Fig. 1). Both anti-TGase 1 and 2 strongly stained vacuoles in SIBM muscle along with b-APP (h, p) and b-A (l, t), and anti-TGase 2
staining also showed strong reaction in the endomysial connective tissues and sarcolemma (j, l, r, t).
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sequences from the heavy chain of skeletal myosin as well as
desmin, an intermediate filament protein believed to be impor-
tant for sarcomeric organization. In addition, an elevated broad
poorly resolved region was found toward the end of the HPLC
profile (Fig. 6), which is reminiscent of highly cross-linked
peptide material recovered from epidermal proteins (31, 35).
Indeed, peptide peak 10 contained nearly stoichiometric se-
quences of both myosin and the intracellular domain of the
b-A4 protein. Since we did not recover a glutamine residue at
cycle 5 as expected for myosin, it is possible that these two
proteins were in fact cross-linked together through Gln421 of
myosin and the downstream Lys751 of the b-APP protein. Ac-
cordingly, these data afford direct evidence for the first time
that the insoluble protein deposits in SIBM are formed in vivo
by TGase cross-linking of amyloid proteins and intracellular
muscle structural proteins.
DISCUSSION
The Presence of TGases 1 and 2 in Muscle Tissues—In this
study, we have demonstrated that at least two members of the
TGase enzyme family are present in muscle tissues; while the
presence of the TGase 2 enzyme is well established, the present
study is the first report on the involvement of the TGase 1
enzyme as well.
The TGase 1 enzyme is abundantly expressed in terminally
differentiating stratified squamous epithelia, wherein it is re-
quired for barrier function by the formation of a cell envelope
by cross-linking a series of defined structural proteins (14, 15,
36). Almost all of the enzyme is membrane-bound (37–39).
During differentiation, some is proteolytically processed into
forms with up to a 200-fold increase in specific activity (39).
Thus, TGase 1 or total TGase activity levels can be increased by
large amounts with only modest increases in TGase 1 expres-
sion. The properties of the TGase 2 enzyme are likewise com-
plex. This protein serves as the Gah protein involved in signal
transduction in most mammalian cells (40). However, when
Ca21 concentrations rise significantly above normal intracellu-
lar levels, this ubiquitous protein becomes active in cross-
linking TGase reactions (14, 15) and is largely cytosolic (11–
15). Furthermore, it cannot be activated by any known process,
and indeed, unlike TGase 1 or the factor XIIIa enzyme, it is
inactivated when proteolyzed (10). It has been implicated in
various processes such as apoptosis (41, 42), wound healing
(43), and extracellular matrix stabilization (44–47). These last
two observations have indicated that TGase 2 can function in
the extracellular environment as well. Indeed, a recent elegant
study has demonstrated that the TGase 2 enzyme binds to
pericellular fibronectin through its amino-terminal b-sandwich
domain (47). In this regard, in muscle tissues, the TGase 2
enzyme has been reported in the basal lamina and perimysial
FIG. 4. Immunohistochemical analyses reveal that TGase ex-
pression does not coincide with CD81 T cell antigens in SIBM
muscle tissue. We performed immunohistochemical staining on serial
frozen sections from SIBM using specific antibodies: TGase 2 (a), CD8
(b), and double immunostaining of TGase 2 (green) and CD8 (red) (c).
The expression of TGase 2 or TGase 1 (not shown) was not colocalized
with the CD81 cells. Magnification was 3 400.
FIG. 5. The presence of insoluble cross-linked high molecular
weight proteins in SIBM tissues. Western blotting with anti-b-A
antibodies revealed high molecular weight proteins at the stacking gel
interface (arrowhead) as well as the expected molecular weight (arrow-
head; 110 kDa). Based on amino acid analyses, the two bands in the
60–70-kDa range are probably minor (,5%) breakdown products of
b-APP.
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connective tissue of heart muscle (13, 16). TGase 2 may con-
tribute to the stability of the postsynaptic cholinergic system,
since it was detected at neuromuscular junctions during nor-
mal neural development (17). Also, it cross-links muscle pro-
teins in different systems (18, 19). Furthermore, one study
using fetal rat myotubes reported the presence of equivalent
amounts of particulate and cytosolic TGase activity (16), but
detailed characterization was not performed. Likewise, we
have found that 25–40% of total TGase activity in mouse skel-
etal muscle homogenates is present in the membrane fraction.2
Based on the known properties of these two enzymes, our new
data suggest that most TGase activity in normal muscle is the
TGase 2 enzyme, and the significant activity present in partic-
ulate fractions is probably due to the membrane-bound TGase
1 enzyme.
Increased Expression of TGases 1 and 2 in SIBM Disease—
Further, our new data reveal that the total levels of TGase
enzyme activity are increased 20-fold in SIBM tissue. This is
accompanied by a substantial increase in levels of the TGase 1
and 2 mRNAs. Although we cannot exclude the possibility in
SIBM muscle tissues, to date there are no reports on widely
differential mRNA stabilities for TGases 1 and 2 in epithelia
(15). Thus, it is unlikely that the 4-fold increase in mRNA for
TGase 2 in SIBM tissues can account for the large increase in
total TGase activity. Therefore, based on the known properties
of the two enzymes, we suggest that the activity increase may
be due in significant part to abnormal proteolytic activation of
TGase 1 in SIBM tissue. However, we cannot exclude the
possibility that other known or as yet unknown TGases may
also contribute to this increase (48). Nevertheless, further de-
tailed studies on the role and biochemistry of TGase 1 in
normal and diseased muscle tissue are warranted.
Two types of data reported here point to the conclusion that
this elevated TGase expression is associated with SIBM patho-
genesis. First, the immunofluorescence showed a striking co-
localization of abnormal deposits and/or vacuolar structures
and increased TGase 1 and 2 deposition (Fig. 2). Second, we
recovered significant amounts of high molecular weight pro-
teins from SIBM tissues (;15% of total tissue protein mass)
that contained about 6 residues/1000 residues of the Ne-(g-
glutamyl)lysine isopeptide cross-link formed specifically by
TGases. In contrast, we found only trace amounts of the cross-
link in normal muscle tissue from the same body site. Typically
proteins cross-linked to this extent in vitro form insoluble mac-
romolecular aggregates (11). In natural phenomena such as
apoptosis in vivo, these insoluble aggregates or complexes are
toxic for cells (15, 41). In this way, we suggest that abnormal
expression and/or activation of TGases may progressively con-
tribute to the pathogenesis of SIBM disease.
The Role of Increased Expression of Amyloid Proteins in
SIBM—Our RT-PCR data confirm earlier findings (9) of a
severalfold increase in b-APP proteins in SIBM tissue (Fig. 2).
Also, we found a marked apparent increase and a striking
co-localization of both b-A and b-APP proteins and TGase en-
zymes over abnormal deposits and vacuolar inclusions in sec-
tions of SIBM tissue (Fig. 3). Furthermore, our new sequencing
data revealed that at least some of the insoluble cross-linked
protein aggregates recovered from SIBM tissues was derived
from the b-APP protein (Table I). Several recent reports have
demonstrated that TGase 2 can cross-link the b-A (49, 50) or
b-APP (51) peptides to dimers and polymers in vitro. Taken
together, our new data suggest that the TGase 1 enzyme, as
well as TGase 2, cross-link these in vivo in diseased SIBM
tissue.
The biological function of b-APP is uncertain, but it is a type
I membrane protein and has been suggested to play roles in
mediating cell-to-cell and cell-to-matrix interactions, mainte-
nance of cell integrity and shape, and neuritic growth (52, 53).
The b-APP gene produces at least three alternatively spliced
transcripts encoding b-APP species containing 695, 751, or 770
amino acids (53). In SIBM, three epitopes of b-APP, amino and
carboxyl termini and b-A, were increased and closely co-local-
ized (54). b-APP mRNA (751 and/or 770) is strongly increased2 S.-Y. Kim, P. M. Steinert, and Y.-C. Choi, unpublished observations.
FIG. 6. HPLC separation of tryptic
peptides derived from insoluble pro-
teins harvested from SIBM muscle
tissue. Of 26 peptides collected for se-
quencing analyses, the identified 10
peaks yielded the recognizable sequences
listed in Table I.
TABLE I
Amino acid sequences and identities of peaks recovered
from HPLC column
The peak numbers are as in Fig. 6. Note that most sequences shown
represent only partial sequences of the tryptic peptide derived from the
protein; thus, peptide 8 contains a Tyr 4 residues downstream.
Peak Sequence Comments
1 FANYIEK Desmin, 119–125, 1A rod domain segment
2 YLETPGDENE b-APP, 378–387, extracellular domain
3 ISYGNDAL b-APP, 576–583, extracellular domain
4 INLPIQTYSA Desmin, 415–428, tail domain
5 AAYLTSLNSA Myosin, 387–399, rod domain
6 LALENYITAL b-APP, 471–480, extracellular domain
7 QYTSIHHGV b-APP, 727–735, intracellular domain
8 QEAPPHIFSI Myosin, 149–158, head domain
9 YAA-MIYTY Myosin, 110–118, head domain
10 GQTV-QVYN Myosin, 417–432, rod domain
QYTSIHHG b-APP, 727–735, intracellular domain
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in muscle fibers (Ref. 9; Fig. 2). In addition, accumulation of
b-APP and its mRNA have been demonstrated in normal neu-
romuscular junctions (55). Thus, it may have a specific function
at the normal neuromuscular synapse. b-APP may also play a
role in early muscle development. However, extant data sug-
gest that its excess expression in mature adult muscle fibers
may be cytotoxic (14, 56).
Insoluble Proteins Obtained from SIBM Include Both Intra-
cellular and Intercellular Proteins: Consequences for SIBM
Pathogenesis—Our data of Fig. 4 suggest that the increased
expression of the TGase enzymes is probably not contributed by
inflammatory cells that infiltrate the diseased muscle tissue
(Fig. 4). However, we cannot ascertain whether the enzymes
are located and functioning intra- or extracellularly (or both)
because of the nature and extent of tissue degeneration of our
specimens. Indeed, high resolution immunological methods at
the electron microscope level, as well as availability of early
disease onset tissues, may be required to provide an unambig-
uous answer.
Numerous proteins have been suggested as components of
the inclusion bodies, based on immunological cross-reactivities
(55, 57). Our new sequencing data clearly indicate that the
protein deposits consist of several proteins rendered insoluble
by extensive (0.6 residues/100 residues) cross-linking by the
isopeptide bond. Most of the peptide peaks recovered in Fig. 6
apparently originated from the less cross-linked portions of the
proteins entrapped in the insoluble macromolecular complex.
These included the intracellular contractile muscle proteins
myosin heavy chain and the intermediate filament structural
protein desmin as well as b-APP sequences. This latter finding
is in direct support of the earlier immunologic findings (55, 57).
The recovery of contractile proteins thus points toward both
intracellular as well as possible intercellular cross-linking by
the increased TGase activities. Clearly, additional protein se-
quencing work using larger amounts of insoluble inclusion
body proteins will be required to characterize the numerous
minor peptide peaks seen in this study and to confirm whether
they contain the many other proteins predicted to be present
(55, 57). Specifically, it would be desirable to better character-
ize the tantalizing broad peak found late in the HPLC profile
(Fig. 6), which is suggestive of tightly cross-linked peptide
material (31, 35). Furthermore, sufficient inclusion body mate-
rial from earlier stages of disease onset would be desirable to
provide temporal information on the roles of the multiple
TGases as well as disease progression.
Conclusions—Here we report that significantly elevated
TGase 1 and 2 expression in the SIBM is correlated with
markedly increased deposition of inclusion bodies containing
highly cross-linked amyloid and other proteins, which may
thereby contribute to the cascade of debilitating muscle disease
in SIBM. Interestingly, pharmacological agents to attenuate
the progression of symptoms of Alzheimer’s disease also have
an inhibitory effect on TGase-induced b-A cross-linking (58).
Thus, our new findings suggest possible approaches for design-
ing of TGase-targeted therapies in SIBM.
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